Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer
References (56)
- et al.
Stage III non-small cell lung cancer (NSCLC): Short course multimodality treatment with accelerated fractionation radiation, concurrent cisplatin/paclitaxel chemotherapy and surgery
Lung Cancer
(1997) - et al.
Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team
J Thorac Cardiovasc Surg
(2000) - et al.
Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
J Biol Chem
(1997) - et al.
Tumour site, sex, and survival in colorectal cancer
Lancet
(2000) - et al.
Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
Lancet
(1996) - et al.
Detection of chromosome 3p alterations in serum DNA of non-small cell lung cancer patients
Ann Oncol
(1998) Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
BMJ
(1995)- et al.
Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience
J Clin Oncol
(1991) - et al.
Taxol: A novel investigational antimicrotubule agent
J Natl Cancer Inst
(1990) - et al.
Phase II study of Taxol and merbarone and piroxantrone in stage IV non-small cell lung cancer. The Eastern Cooperative Oncology Group results
J Natl Cancer Inst
(1993)
Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer
J Natl Cancer Inst
Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
J Natl Cancer Inst
Paclitaxel plus carboplatin in advanced non-small-cell lung cancer
Oncology
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response and survival analysis
J Clin Oncol
Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial
J Clin Oncol
Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small-cell lung cancer
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-smallcell lung cancer
J Clin Oncol
A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer
Clin Cancer Res
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study
Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
J Clin Oncol
Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
J Clin Oncol
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
J Clin Oncol
A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
Randomized pan-European trial comparing paclitaxel (TAX)/carboplatin versus paclitaxel/cisplatin (CIS) in advanced non-small cell lung cancer (NSCLC)
Eur J Cancer
A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
J Clin Oncol
Cited by (34)
Photodynamic effect of chlorin e6 on cytoskeleton protein of human colon cancer SW480 cells
2021, Photodiagnosis and Photodynamic TherapyCitation Excerpt :It will directly affect the formation of spindle in mitosis and the cells cannot divide normally if microtubule de-polymerization or α and β protein polymerization was destroyed, and tubulin plays a key role in this process [22]. Some studies have found that the abnormal expression of tubulin will lead to the occurrence of malignant behaviors such as abnormal cell proliferation, invasion and metastasis which can be found in many kinds of tumor tissues like gastric cancer, rectal cancer, prostate cancer and lung cancer [23–26]. Our study of western blot demonstrated that the expression of α-tubulin and β-tubulin in SW480 cells decreased significantly after Ce6-PDT (Fig.5).
Raloxifene-encapsulated hyaluronic acid-decorated chitosan nanoparticles selectively induce apoptosis in lung cancer cells
2019, Bioorganic and Medicinal ChemistryCitation Excerpt :Thus, a better understanding of carcinogenic machineries and mechanisms of drug resistance is pivotal for current drug development plans.1,6 In contemporary studies, specific mutagenic inhibitors have been exploited in lung cancer treatment; however, these therapeutic strategies are only suitable for specific rare mutagenic cases,7,8 of which the majority eventually develop chemo-resistance.9 Therefore, there is an urgent need for the development of new therapeutic approaches for NSCLC.
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer
2010, Critical Reviews in Oncology/HematologyCitation Excerpt :In NSCLC patients treated with surgery alone, high class III β-tubulin expression was associated with poorer relapse-free and overall survival [290]. In locally advanced or metastatic NSCLC treated with taxane-containing regimens, patients with tumor β-tubulin mutations had substantially lower response rates [288] or a trend towards lower response rates [287] than did patients with wild type β-tubulin. Response rates were also lower in patients with high tumor expression of β-tubulin III compared to those with low expression [291,292].
Pharmacogenomics in non-small-cell lung cancer chemotherapy
2009, Advanced Drug Delivery ReviewsThe role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer
2007, Journal of Thoracic OncologyCitation Excerpt :Therefore, the mutational and gene expression analysis of tubulin isotypes could be of critical importance in assessing the sensitivity of cancer cells toward taxanes. β tubulin class I mutation had been described in patients with NSCLC 26 and was identified in 33% of patients with NSCLC, none of whom had an objective response to paclitaxel treatment.27 The up-regulation of βIII isotype is another important marker of resistance, and high concentrations of βIII-tubulin are associated with a decrease in paclitaxel sensitivity in NSCLC cells.
Additive Effects of TRAIL and Paclitaxel on Cancer Cells: Implications for Advances in Cancer Therapy
2004, Vitamins and HormonesCitation Excerpt :One possible new strategy in the cancer treatment is to combine chemotherapeutic agents with proapoptotic genes or molecules to enhance the apoptotic death of tumor cells. Through many clinical trials, PA antitumor activity has been observed and improved by its combination with several known antitumor drugs, such as platinum, carboplatin, anthracyclins, doxorubicin, cisplatin, or docetaxel (Belani, 2000; Bunn, Jr. et al., 2000; Nabholtz et al., 2001; Novello et al., 2001; Perez, 2001; Rosell et al., 2001). New agents, such as antibodies, or modified genes are also presently investigated (Perez, 1999).
- 1
Dr Rosell has received research grant support from the Bristol-Myers Squibb COMET Program.